| Not Yet Recruiting | QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma NCT07463573 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors NCT07189871 | Radiopharm Theranostics, Ltd | Phase 1 / Phase 2 |
| Not Yet Recruiting | Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable E NCT07403435 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Not Yet Recruiting | Standardized Management of Esophageal Fistula in Esophageal Squamous Cell Carcinoma NCT07353541 | Peking University Cancer Hospital & Institute | — |
| Not Yet Recruiting | Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Co NCT06952621 | Tang-Du Hospital | Phase 3 |
| Not Yet Recruiting | Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Inva NCT07376876 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 2 |
| Not Yet Recruiting | A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory NCT07272291 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Not Yet Recruiting | Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induct NCT07246330 | Tianjin Medical University Cancer Institute and Hospital | Phase 3 |
| Recruiting | KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Ca NCT07481058 | Beijing Konruns Pharmaceutical Co., Ltd. | Phase 2 |
| Active Not Recruiting | Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable NCT07339488 | Chuangzhen Chen | Phase 2 |
| Recruiting | Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, Wit NCT07205731 | University Hospital, Clermont-Ferrand | Phase 2 |
| Recruiting | Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Ca NCT07039162 | Ming-Yu Lien | Phase 2 |
| Recruiting | The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line NCT07290010 | Hebei Medical University Fourth Hospital | Phase 2 |
| Not Yet Recruiting | Multi-omics Monitoring of Dynamic Evolution in Esophageal Squamous Cell Carcinoma: PKU-ESCC-Monitor NCT07152535 | Peking University Cancer Hospital & Institute | — |
| Recruiting | A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors NCT07085091 | ALX Oncology Inc. | Phase 1 |
| Active Not Recruiting | A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastati NCT07142421 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Not Yet Recruiting | Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma NCT07067450 | Sichuan University | N/A |
| Recruiting | Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer NCT07317609 | Shanghai Zhongshan Hospital | Phase 1 |
| Recruiting | MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell Carcinoma NCT07359417 | UMC Utrecht | Phase 1 |
| Recruiting | Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esoph NCT06912074 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC NCT06861777 | YIN LI | Phase 2 / Phase 3 |
| Not Yet Recruiting | Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcin NCT06746961 | The First Affiliated Hospital of Zhengzhou University | Phase 1 / Phase 2 |
| Active Not Recruiting | Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, NCT06504615 | Bristol-Myers Squibb | — |
| Recruiting | A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy fo NCT06709417 | Shanghai Chest Hospital | Phase 2 |
| Active Not Recruiting | NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC NCT06762158 | RenJi Hospital | N/A |
| Recruiting | Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma NCT06675201 | Sichuan University | Phase 2 |
| Recruiting | Tumor Regression Grade As Predictor of Adjuvant Therapy NCT06710665 | Fujian Medical University Union Hospital | — |
| Enrolling By Invitation | A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for NCT06863831 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | N/A |
| Enrolling By Invitation | Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After D NCT07016737 | Ye jinjun | Phase 3 |
| Recruiting | A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer NCT07224750 | City of Hope Medical Center | — |
| Unknown | IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC) NCT06078657 | The First Affiliated Hospital of Zhengzhou University | Phase 2 |
| Recruiting | Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC NCT06603402 | Sichuan University | Phase 2 |
| Recruiting | A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally A NCT05473156 | AP Biosciences Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants W NCT05342636 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Active Not Recruiting | Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma NCT07147361 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | — |
| Completed | BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study) NCT04839471 | National Health Research Institutes, Taiwan | Phase 2 |
| Recruiting | An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy NCT07080437 | Three Gorges Hospital of Chongqing University | — |
| Active Not Recruiting | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Ch NCT04210115 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy NCT03957590 | BeiGene | Phase 3 |
| Completed | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants Wi NCT03783442 | BeiGene | Phase 3 |
| Completed | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With A NCT03708328 | Hoffmann-La Roche | Phase 1 |
| Completed | Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC NCT07236320 | Yongtao Han | N/A |
| Completed | A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced NCT03430843 | BeiGene | Phase 3 |
| Completed | Neoadjuvant Chemoradiotherapy Plus Surgery vs. Surgery Plus Adjuvant Therapy for ESCC NCT06775652 | Yongtao Han | Phase 3 |